Identification and validation of non-canonical RET-fusions in non-small-cell lung cancer through DNA and RNA sequencing
Source : https://www.jmdjournal.org/article/S1525-1578(22)00009-5/fulltext
RET fusion has emerged as a targetable driver in non-small-cell lung cancer (NSCLC). A comparative analysis on RET fusions at DNA (DNA-seq) and RNA (RNA-seq) levels was performed in this...
Conclusion/Relevance: RET fusion has emerged as a targetable driver in non-small-cell lung cancer (NSCLC). A comparative analysis on RET fusions at DNA (DNA-seq) and RNA (RNA-seq) levels was performed in this study.
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34928484/
doi: 10.1007/s40264-021-01127-2. 1 Catalan Institute of Oncology, IDIBELL, L'Hospitalet, Barcelona, Spain. [email protected]. 2 National Cancer Center Hospital, Tokyo, Japan. 3 National Taiwan University Hospital, Taipei City, Taiwan. 4 Faculty of...
Conclusion: This in-depth safety analysis from RELAY supports that RAM ERL, irrespective of the increased incidence of AEs, does not affect a patient's ability to benefit from treatment.
Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study - Investigational New Drugs
Source : https://link.springer.com/article/10.1007/s10637-022-01214-w
Objective. Ramucirumab plus docetaxel (RAM/DOC) therapy is currently the standard for previously treated advanced non-small cell lung cancer (NSCLC), irrespective of histology. However, in the clinical trial, only the first-line...
Conclusions: For previously treated patients with Sq, the efficacy and safety of RAM/DOC therapy were confirmed in a real-world setting and were similar to non-Sq.
DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer
Source : https://www.sciencedirect.com/science/article/pii/S2211383521002781?via=ihub
A significant proportion of non-small cell lung cancer (NSCLC) patients experience accumulating chemotherapy-related adverse events, motivating the design of chemosensitizating strategies. The main cytotoxic damage induced by chemotherapeutic agents is...
Conlcusion/Relevance: The present study provides a theoretical basis for the use of M3814 in combination with paclitaxel and etoposide in clinical practice, with hope to aid the optimization of NSCLC treatment.
-
NSCLC Connect4yrKey Points • Source: Acta Pharmaceutica Sinica B • Relevance: “The present study aims to systematically evaluate the efficacy and safety of a novel DNA-PK inhibitor M3814 in synergy with chemotherapies on NSCLC.” • Double-strand breaks Show More
Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer
Source : https://onlinelibrary.wiley.com/doi/10.1111/cas.15263
Takamasa Koga , Kenichi Suda , Tetsuya Mitsudomi , Corresponding Author Tetsuya Mitsudomi Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan Corresponding author...
Conclusion/Relevance: We demonstrated that 68% of resistance mutations reproducibly detected in clinical cases were also found in Ba/F3 models. In addition, sensitivity data generated with Ba/F3 models correlated well with clinical responses to each drug. Ba/F3 models is useful to comprehensively identify potential mutations that induce...